Nippon Express Co., Ltd. (Satoshi Horikiri, President; hereafter “Nippon Express”), a group company of NIPPON EXPRESS HOLDINGS, INC. (Mitsuru Saito, President), has acquired Good Distribution Practice (GDP) certification for its West Japan Pharmaceutical Center (Neyagawa City, Osaka Prefecture) effective November 20, 2022 and its Kyushu Pharmaceutical Center (Kitakyushu City, Fukuoka Prefecture) effective December 21, 2022, evidencing their compliance with WHO standards for the proper distribution of pharmaceuticals.
The Nippon Express Group has positioned the pharmaceutical industry as a key industry in its “Nippon Express Group Business Plan 2023 ~Dynamic Growth~,” and has been developing a safe and secure pharmaceutical logistics platform to meet sophisticated and diverse pharmaceutical logistics needs globally.
The West Japan Pharmaceutical Center and the Kyushu Pharmaceutical Center, both of which are dedicated logistics bases for pharmaceuticals, recently obtained GDP certification of their conformity to WHO standards for the storage and transport of pharmaceutical products in two temperature ranges (room temperature [15°-25°C] and refrigerated [2°-8°C]), the same certification that the East Japan Pharmaceutical Center (Kuki City, Saitama Prefecture) acquired in July 2022. The Nippon Express now has 34 business locations in 24 countries/regions around the world with GDP, CEIV Pharma or other certifications for pharmaceutical logistics, helping the Group better provide safe and high-quality pharmaceutical logistics services on an end-to-end basis globally with these certifications at the heart of its services.
Going forward, the Nippon Express Group will continue offering solutions to the challenges faced by the pharmaceutical industry, thereby enhancing the value of pharmaceuticals through logistics and contributing to the health of those who need them.
Source: Nippon Express
